Highlights of weekly biotech stock moves

Corcept Therapeutics Inc. (NASDAQ:CORT) fell $0.30 (16%) to $1.60 on Wednesday after FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from competitor Novartis AG (NYSE:NVS; SIX:NOVN) support approval to treat Cushing's disease. The PDUFA date is not disclosed. Corcept markets Korlym mifepristone, the only drug approved in the U.S. to treat Cushing's syndrome.

Last week, the biotech's shares lost $0.64 (33%) to $1.31...